Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aripiprazole effects on reward processing in deficit syndrome schizophrenia.

Trial Profile

Aripiprazole effects on reward processing in deficit syndrome schizophrenia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2013

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jun 2012 Actual patient number is 20 according to ClinicalTrials.gov.
    • 15 Jun 2012 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 15 Jun 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top